1011 Higher Preoperative Serum Biologic Levels Are Associated With Postoperative Complications in Crohn's Disease Patients

Abstract

G A A b st ra ct s on levels (ug/ml): a).0-3, b) .3-8 and c) . 8. Postoperative outcomes within 30 days of surgery were collected prospectively and compared among the 4 groups. Categorical variables were analyzed using Fisher's exact test and continuous variables analyzed with Students' ttest. Results: The study cohort of 94 patients had a median age of 35 years (range, 7-76) and included 45 (48 %) males. Index surgery performed was IPAA in 52 (55%) and STC in 42 (45%) patients. Serum biologic levels were detected in 19 (20%) and negative in 75 (80%) patients. Groups 1 and 2 were similar in age, gender and history of preoperative immunomodulators. There was no statistical significance in the initial use of STC in Group 2 vs. Group 1 patients (63% vs 40%, p=0.07). There were also no significant differences between the 2 groups with regards to overall postoperative morbidity (42% vs. 41%, p = 0.95), infectious complications (11% vs. 13%, p = 0.74) or 30-day readmission rates after surgery (21% vs. 20%, p = 0.92) (Figure). There were no significant associations between increasing serum biologic levels and overall postoperative morbidity, infectious complications and readmission rates after surgery. This lack of association between serum biologic levels and postoperative outcomes were also observed in both the STC and IPAA patients groups individually. Conclusion: The presence and magnitude of serum biologic levels do not adversely influence short-term postoperative outcomes in UC patients. There appears to be no deleterious effect of preoperative biologic drug use in UC patients requiring surgeries.